Compare WKEY & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | PLYX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Switzerland | United States |
| Employees | 202 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 112.7M |
| IPO Year | N/A | N/A |
| Metric | WKEY | PLYX |
|---|---|---|
| Price | $6.12 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.50 | $10.00 |
| AVG Volume (30 Days) | 48.3K | ★ 91.4K |
| Earning Date | 01-28-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $1.86 |
| 52 Week High | $19.80 | $9.18 |
| Indicator | WKEY | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 44.71 |
| Support Level | $5.32 | $2.09 |
| Resistance Level | $8.27 | $2.91 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 32.80 | 54.10 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.